RELATIONSHIP OF BLAST CELL IMMUNOPHENOTYPE WITH REMISSION IN ACUTE MYELOID LEUKEMIA IN CHILDREN

Introduction. Acute myeloid leukemia (AML) is a clonal disease of the blood system that occurs as a result of mutations in the genome of hematopoietic progenitor cells. As a result of mutations, the linear differentiation of hematopoietic cells is replaced by the proliferation of malignant myeloid progenitors. Currently, the risk group for AML in children is determined mainly by the presence of specific gene and chromosomal abnormalities and an increased level of peripheral blood leukocytes. The features of the immunophenotype of blast cells can also influence the course of the disease.

The aim of the work is to assess the relationship between the immunophenotypic parameters of blast cells and the probability of achieving remission in children with AML.

Materials and methods. The study included 109 patients aged 3 months to 17 years who received treatment according to the AML BFM 87, AML BFM 2004, NII DOG AML 2007 и NII DOG AML 2012 protocol in the period from 1991 to 2020.

Results. The study showed the relationship between the probability of achieving remission and the presence of markers CD33, CD19 and CD14 on tumor cells. Expression of lymphoid antigen CD19 on blasts was associated with a higher rate of remission (73.0 % vs 95.5 %, p = 0.027). The absence of the linearly associated myeloid marker CD33 negatively correlated with the remission rate (61.1 % vs 87.7 %, p = 0.007). In the presence of monocyte antigen CD14 on blasts, the probability of achieving remission was low (95 % vs 50 %, p = 0.013).

Conclusion. Characteristics of the immunophenotype of tumor cells in AML in children are associated with the probability of achieving remission.

1. Maschan A.A., Maschan M.A., Novichkova G.A. et al. Clinical recommendations. Acute myeloid leukemia. Ministry of Health of Russia, 2020. Pp. 12–13.(In Russ.).

2. Coustan-Smith E., Song G., Shurtlef S. et al. Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight 2018;3(9):e98561. DOI: 10.1172/jci.insight.98561

3. Papaemmanuil E., Gerstung M., Bullinger L. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 2016;374:2209–21. DOI: 10.1056/NEJMoa1516192.

4. Schuurhuis G.J., Heuser M., Freeman S. et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018;131(12):1275–91. DOI: 10.1182/blood-2017-09-801498.

5. Döhner H., Estey E., Grimwade D. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4):424–47. DOI: 10.1182/blood-2016-08-733196.

6. Jongen-Lavrencic M., Grob T., Hanekamp D. et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med 2018;378(13):1189–99. DOI: 10.1056/NEJMoa1716863.

7. Creutzig U., Harbott J., Sperling C. et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995;86(8): 3097–3108. PMID: 7579404.

8. Casasnovas R.O., Solary E., Campos L. et al. Prognostic Relevance of Surface Markers in Adult de novo Acute Myeloblasts Leukemias: A Prospective Study of the Groupe d’Etude Immunologique des Leucemies (G.E.I.L.). Leukemia & Lymphoma 1994;13:7–10. DOI: 10.3109/10428199409052665.

9. Ball E.D., Davis R.B., Griffin J.D. et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991;77(10):2242–50. PMID: 1709379.

10. Noriyoshi Iriyama, Yoshihiro Hatta, Jin Takeuchi et al. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leukemia Research 2013;37(9):1021–26. DOI: 10.1016/j.leukres.2013.05.002.

11. Kita K., Nakase K., Miwa H. et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80:470–7. PMID: 1378322.

12. de Nully Brown P., Jurlander J., Pedersen-Bjergaard J. et al. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia. Leuk Res 1997;21(10):985–95. DOI: 10.1016/s0145-2126(97)00079-9.

13. Campos L., Guyotat D., Archimbaud E. et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989;72(2):161–6. DOI: 10.1111/j.1365-2141.1989.tb07677.x.

14. Bradstock K., Matthews J., Benson E. et al. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994;84(4):1220–5. PMID: 8049437.

15. San Miguel J.F., Ojeda E., Gonzalez M. et al. Prognostic value of immunological markers in acute myeloblastic leukemia. Leukemia 1989;3(2):108–11. PMID: 2911203.

16. Nikitaev V.G., Pronichev A.N., Polyakov E.V. et al. Bone marrow cells recognition methods in the diagnosis Computer Science 2020;169:353–58. DOI: 10.1016/j.procs.2020.02.229.

17. Buldini B., Rizzati F., Masetti R. et al. Prognostic significance of flowcytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br J Haematol 2017;177(1):116–26. DOI: 10.1111/bjh.14523.